Deadline: April 13, 2020
Pfizer has issued an RFP for Targeted Therapy in Colorectal Cancer.
Grants of up to $250,000 will be awarded to oncologists, advanced practitioners, oncology nurses, and other healthcare professionals involved in the care of patients with colorectal cancer in support of projects with potential to increase the understanding of targeted therapies, including BRAF inhibitors and their use in the treatment of colorectal cancer (CRC). Topics of interest include prevalence of BRAF-mutated CRC; incorporating biomarker and genomic testing into community cancer center standard practice; incorporating the use of targeted therapies into clinical practice; increasing understanding of recent clinical data to help inform the selection of treatment options; monitoring for and managing side effects of therapies; and development of, or access to, patient resources to help improve patient understanding of their options.
Of additional interest are educational initiatives that include a focus on reducing disparities in quality of care for patients due to geographic or socioeconomic factors. Smaller more specialized projects, or those with a local or regional focus, are also encouraged at a lower grant threshold (approximately $25,000 to $100,000). The estimated total available budget under this RFP is $750,000.
Eligible applicants include medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
See the Pfizer website for complete program guidelines and application instructions.Link to Complete RFP